The Saudi Food and Drug Authority (SFDA) has released Version 4 of the Human Drug Submission Guideline, providing updated requirements for the preparation and submission of medicinal product applications in Saudi Arabia. This document serves as a critical reference for regulatory professionals and pharmaceutical companies seeking marketing authorization.

Objective and Scope

The guideline establishes clear instructions for preparing the drug dossier, including format, structure, and content requirements. It applies to:

• New marketing applications
• Variations and renewals of existing authorizations
• Post-marketing commitments

By aligning with international standards such as the Common Technical Document (CTD) format, the SFDA aims to harmonize submissions, improve dossier quality, and facilitate more efficient regulatory reviews.

Key Requirements for Submissions

• Electronic format (eCTD/ NeeS): Submissions must be presented electronically, following the SFDA’s technical specifications.
• Administrative and product information: Including application forms, proof of authorization, and labeling documents.
• Module 2 (Summaries): High-level overviews of quality, non-clinical, and clinical data.
• Module 3 (Quality): Comprehensive data on manufacturing, controls, stability, and specifications.
• Module 4 (Non-clinical): Pharmacology and toxicology studies.
• Module 5 (Clinical): Clinical trial data, biopharmaceutics, and efficacy/safety evidence.

Good Submission Practices (GSPs)

• Submitting complete and well-structured dossiers to avoid delays.
• Ensuring data integrity and alignment with ICH and WHO standards.
• Using SFDA-provided templates and checklists for consistency.
• Maintaining clear communication with SFDA throughout the submission and review process.

Review Process

Applications undergo two main stages:

1. Validation – to confirm dossier completeness and compliance.
2. Scientific review – a multidisciplinary evaluation of safety, efficacy, and quality.

Depending on product type and public health needs, submissions may follow regular, priority, or reliance pathways. The reliance mechanism allows SFDA to consider assessments and approvals from other stringent regulatory authorities, reducing review timelines where appropriate.

Implications for Industry

• Streamlining application timelines
• Minimizing deficiencies and queries during review
• Enhancing alignment with global submission practices
• Supporting faster patient access to innovative medicines in Saudi Arabia

Conclusion

The Human Drug Submission Guideline (V.4) reflects SFDA’s commitment to harmonization, transparency, and efficiency in regulatory decision-making. For pharmaceutical companies, adopting the guideline’s requirements and good submission practices is critical to ensuring successful market entry and lifecycle management in Saudi Arabia.